

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1248	((514/109) or (514/720) or (514/721) or (568/646) or (568/17)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2006/05/11 07:59
L2	1081	resveratrol	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/05/11 07:59
L3	6	l1 and l2	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/05/11 08:25
L4	1734	4-hydroxybenzaldehyde or (4-methoxybenzy near2 bromide)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/05/11 08:44
L5	1	l2 and l4	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/05/11 08:30
L6	1449	pettit.in. or grealish.in.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/05/11 08:31
L7	4	l2 and l6	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/05/11 08:31
L8	1963	4-hydroxybenzaldehyde or (4-methoxybenzyl near2 bromide)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/05/11 08:45
L9	1	l2 and l8	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/05/11 08:46

EAST Search History

L10	218885	cancer	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/05/11 08:46
L11	555	I2 and I10	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/05/11 08:51
L12	1311	otbdms! or tert-butyldimethylsilyloxy	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/05/11 09:00
L13	1	I11 and I12	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/05/11 09:00
L14	5	I2 and I12	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/05/11 10:36
L15	2	("2002119951").PN.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2006/05/11 10:37
L16	2	("20020119951").PN.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2006/05/11 10:48
L17	3	("7018987").PN.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2006/05/11 11:17
L18	537838	phosphate	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/05/11 11:17
L19	594	I2 and I18	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/05/11 11:17

EAST Search History

L20	123	I2 same I18	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/05/11 11:17
-----	-----	-------------	---	----	----	------------------

10/510,675

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1204rxw

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	DEC 23	New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/ USPAT2
NEWS	4	JAN 13	IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS	5	JAN 13	New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC
NEWS	6	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS	7	JAN 17	IPC 8 in the WPI family of databases including WPIFV
NEWS	8	JAN 30	Saved answer limit increased
NEWS	9	FEB 21	STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS	10	FEB 22	The IPC thesaurus added to additional patent databases on STN
NEWS	11	FEB 22	Updates in EPFULL; IPC 8 enhancements added
NEWS	12	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS	13	FEB 28	MEDLINE/LMEDLINE reload improves functionality
NEWS	14	FEB 28	TOXCENTER reloaded with enhancements
NEWS	15	FEB 28	REGISTRY/ZREGISTRY enhanced with more experimental spectral property data
NEWS	16	MAR 01	INSPEC reloaded and enhanced
NEWS	17	MAR 03	Updates in PATDPA; addition of IPC 8 data without attributes
NEWS	18	MAR 08	X.25 communication option no longer available after June 2006
NEWS	19	MAR 22	EMBASE is now updated on a daily basis
NEWS	20	APR 03	New IPC 8 fields and IPC thesaurus added to PATDPAFULL
NEWS	21	APR 03	Bibliographic data updates resume; new IPC 8 fields and IPC thesaurus added in PCTFULL
NEWS	22	APR 04	STN AnaVist \$500 visualization usage credit offered
NEWS	23	APR 12	LINSPEC, learning database for INSPEC, reloaded and enhanced
NEWS	24	APR 12	Improved structure highlighting in FQHIT and QHIT display in MARPAT
NEWS	25	APR 12	Derwent World Patents Index to be reloaded and enhanced during second quarter; strategies may be affected
NEWS	26	MAY 10	CA/CAPLUS enhanced with 1900-1906 U.S. patent records
NEWS EXPRESS			FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005. V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT http://download.cas.org/express/v8.0-Discover/
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

10/510,675

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

COMPLETE THE STN SURVEY - APRIL 27 THROUGH MAY 31

Dear valued STN customer,

In an effort to enhance your experience with STN, we would like to better understand what you find useful. Please take approximately 5 minutes to complete a web survey.

If you provide us with your name, login ID, and e-mail address, you will be entered in a drawing to win a free iPod(R). Your responses will be kept confidential and will help us make future improvements to STN.

Take survey: <http://www.zoomerang.com/survey.zgi?p=WEB2259HNKWTUW>

Thank you in advance for your participation.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 09:27:33 ON 11 MAY 2006

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 09:27:38 ON 11 MAY 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 10 MAY 2006 HIGHEST RN 883788-13-4

DICTIONARY FILE UPDATES: 10 MAY 2006 HIGHEST RN 883788-13-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

10/510,675

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:


<http://www.cas.org/ONLINE/UG/regprops.html>

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=>

Uploading C:\Documents and Settings\rkeys\My Documents\STNEXP4\TEMPLATE\STANDARD\10510675.str



chain nodes :

1 2 15 16 17 18 19 21 22

ring nodes :

3 4 5 6 7 8 9 10 11 12 13 14 25 26 27 28 29 30 31 32 33 34 35
36

chain bonds :

1-2 1-4 2-3 15-16 16-17 16-18 16-19 18-25 19-26

ring bonds :

3-10 3-14 4-5 4-9 5-6 6-7 7-8 8-9 10-11 11-12 12-13 13-14 25-27 25-31
26-32 26-36 27-28 28-29 29-30 30-31 32-33 33-34 34-35 35-36

exact/norm bonds :

15-16 16-17 16-18 16-19 18-25 19-26

exact bonds :

1-2 1-4 2-3

normalized bonds :

3-10 3-14 4-5 4-9 5-6 6-7 7-8 8-9 10-11 11-12 12-13 13-14 25-27 25-31
26-32 26-36 27-28 28-29 29-30 30-31 32-33 33-34 34-35 35-36

isolated ring systems :

containing 3 : 4 : 25 : 26 :

Match level :

1:CLASS 2:CLASS 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:Atom 26:Atom
27:Atom 28:Atom 29:Atom 30:Atom 31:Atom 32:Atom 33:Atom 34:Atom 35:Atom
36:Atom


L1 STRUCTURE UPLOADED

=> que L1

L2 QUE L1


10/510,675

=> d
L2 HAS NO ANSWERS
L1 STR



3

Page 1-A



Page 1-B

32

Page 2-B
VPA 15-10/11/12/13 S

10/510,675

VPA 20-5/6/7/8/9 S

VPA 21-5/6/7/8/9 S

NODE ATTRIBUTES:

HCOUNT	IS	E3	AT	34
HCOUNT	IS	E3	AT	35
NSPEC	IS	C	AT	1
NSPEC	IS	C	AT	2
NSPEC	IS	R	AT	3
NSPEC	IS	R	AT	4
NSPEC	IS	R	AT	5
NSPEC	IS	R	AT	6
NSPEC	IS	R	AT	7
NSPEC	IS	R	AT	8
NSPEC	IS	R	AT	9
NSPEC	IS	R	AT	10
NSPEC	IS	R	AT	11
NSPEC	IS	R	AT	12
NSPEC	IS	R	AT	13
NSPEC	IS	R	AT	14
NSPEC	IS	C	AT	15
NSPEC	IS	C	AT	16
NSPEC	IS	C	AT	17
NSPEC	IS	C	AT	18
NSPEC	IS	C	AT	19
NSPEC	IS	C	AT	20
NSPEC	IS	C	AT	21
NSPEC	IS	R	AT	22
NSPEC	IS	R	AT	23
NSPEC	IS	R	AT	24
NSPEC	IS	R	AT	25
NSPEC	IS	R	AT	26
NSPEC	IS	R	AT	27
NSPEC	IS	R	AT	28
NSPEC	IS	R	AT	29
NSPEC	IS	R	AT	30
NSPEC	IS	R	AT	31
NSPEC	IS	R	AT	32
NSPEC	IS	R	AT	33
NSPEC	IS	C	AT	34
NSPEC	IS	C	AT	35

DEFAULT MLEVEL IS ATOM

MLEVEL IS CLASS AT 1 2 15 16 17 18 19 20 21 34 35

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RSPEC I

NUMBER OF NODES IS 35

STEREO ATTRIBUTES: NONE

L2 QUE L1

=> s 12

SAMPLE SEARCH INITIATED 09:28:15 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 29 TO ITERATE

100.0% PROCESSED 29 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 257 TO 903

PROJECTED ANSWERS: 0 TO 0

10/510,675

L3 0 SEA SSS SAM L1

=> s l2 ful

FULL SEARCH INITIATED 09:28:21 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 522 TO ITERATE

100.0% PROCESSED 522 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

L4 0 SEA SSS FUL L1

=> file stnguide

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

167.82

168.03

FILE 'STNGUIDE' ENTERED AT 09:29:22 ON 11 MAY 2006

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE

AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: May 5, 2006 (20060505/UP).

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.42

168.45

FILE 'REGISTRY' ENTERED AT 09:33:21 ON 11 MAY 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 10 MAY 2006 HIGHEST RN 883788-13-4

DICTIONARY FILE UPDATES: 10 MAY 2006 HIGHEST RN 883788-13-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information

10/510,675

on property searching in REGISTRY, refer to:


<http://www.cas.org/ONLINE/UG/regprops.html>

=>Testing the current file..... screen

ENTER SCREEN EXPRESSION OR (END):end

=>

Uploading C:\Documents and Settings\rkeys\My
Documents\STNEXP4\TEMPLATE\STANDARD\10510675a.str



chain nodes :

1 2 15 16 17 18 19 21 22

ring nodes :

3 4 5 6 7 8 9 10 11 12 13 14

chain bonds :

1-2 1-4 2-3 15-16 16-17 16-18 16-19

ring bonds :

3-10 3-14 4-5 4-9 5-6 6-7 7-8 8-9 10-11 11-12 12-13 13-14

exact/norm bonds :

15-16 16-17 16-18 16-19

exact bonds :

1-2 1-4 2-3

normalized bonds :

3-10 3-14 4-5 4-9 5-6 6-7 7-8 8-9 10-11 11-12 12-13 13-14

isolated ring systems :

containing 3 : 4 :

Match level :

1:CLASS 2:CLASS 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS

L5 STRUCTURE UPLOADED

=> que L5

L6 QUE L5

=> s 16

SAMPLE SEARCH INITIATED 09:33:41 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 45 TO ITERATE

100.0% PROCESSED 45 ITERATIONS

8 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

10/510,675

PROJECTED ITERATIONS: 498 TO 1302
PROJECTED ANSWERS: 8 TO 329

L7 8 SEA SSS SAM L5

=> s l6 ful

FULL SEARCH INITIATED 09:33:50 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 797 TO ITERATE


100.0% PROCESSED 797 ITERATIONS 159 ANSWERS
SEARCH TIME: 00.00.01

L8 159 SEA SSS FUL L5

=> d scan

L8 159 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Phenol, 2-bromo-6-methoxy-3-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-,
dihydrogen phosphate (9CI)
MF C18 H20 Br O8 P
CI COM

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

167.38

335.83

FILE 'CAPLUS' ENTERED AT 09:34:34 ON 11 MAY 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 11 May 2006 VOL 144 ISS 20

FILE LAST UPDATED: 9 May 2006 (20060509/ED)

10/510,675

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> d his

(FILE 'HOME' ENTERED AT 09:27:33 ON 11 MAY 2006)

FILE 'REGISTRY' ENTERED AT 09:27:38 ON 11 MAY 2006

L1 STRUCTURE UPLOADED
L2 QUE L1
L3 0 S L2
L4 0 S L2 FUL

FILE 'STNGUIDE' ENTERED AT 09:29:22 ON 11 MAY 2006

FILE 'REGISTRY' ENTERED AT 09:33:21 ON 11 MAY 2006

L5 STRUCTURE UPLOADED
L6 QUE L5
L7 8 S L6
L8 159 S L6 FUL

FILE 'CAPLUS' ENTERED AT 09:34:34 ON 11 MAY 2006

=> s l8

L9 145 L8

=> dup rem l9

PROCESSING COMPLETED FOR L9

L10 145 DUP REM L9 (0 DUPLICATES REMOVED)

=> s l10 and cancer

L11 145 S L10
277895 CANCER
L12 64 L11 AND CANCER

=> d 1-64 ti

L12 ANSWER 1 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
TI Pyrazolopyrimidines as protein kinase B inhibitors, their preparation,
pharmaceutical compositions, and use in therapy

L12 ANSWER 2 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of halocombstatis for use in pharmaceutical compositions for
the treatment of **cancer**

L12 ANSWER 3 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of carboline derivatives as antitumor agents

L12 ANSWER 4 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
TI Vascular damaging agents, such as ZD6126 for administration as an
intravenous infusion for treatment of solid tumors

L12 ANSWER 5 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
TI Antineoplastic Agents. 509. Synthesis of Fluorcombstatin Phosphate and
Related 3-Halostilbenes

L12 ANSWER 6 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
TI Methods for detecting AC133 antigen mRNA for diagnosis and treatment of
cancer and other diseases

L12 ANSWER 7 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN

- TI Preparation of combretastatin halogen derivatives for use in pharmaceutical compositions for the treatment of **cancer**

- L12 ANSWER 8 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
- TI Plants as a source of anti-**cancer** agents

- L12 ANSWER 9 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
- TI Vascular Targeting and Antiangiogenesis Agents Induce Drug Resistance Effector GRP78 within the Tumor Microenvironment

- L12 ANSWER 10 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
- TI Disrupting tumor blood vessels

- L12 ANSWER 11 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
- TI Antineoplastic Agents. 445. Synthesis and Evaluation of Structural Modifications of (Z)- and (E)-Combretastatin A-4

- L12 ANSWER 12 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
- TI Improved combination bacteriolytic therapy for the treatment of tumors using spores of anaerobic bacteria and microtubule agents

- L12 ANSWER 13 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
- TI Tumour parameters affected by combretastatin A-4 phosphate therapy in a human colorectal xenograft model in nude mice

- L12 ANSWER 14 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
- TI Phase I trial of combretastatin A-4 phosphate with carboplatin

- L12 ANSWER 15 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
- TI Preparation of combretastatin derivatives for use in pharmaceutical compositions for the treatment of **cancer** and other hyperproliferative diseases

- L12 ANSWER 16 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
- TI Measuring tumour vascular response to antivascular and antiangiogenic drugs

- L12 ANSWER 17 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
- TI Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging

- L12 ANSWER 18 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
- TI Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results

- L12 ANSWER 19 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
- TI Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with **cancer**: magnetic resonance imaging evidence for altered tumor blood flow

- L12 ANSWER 20 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
- TI Characterization of the Hollow Fiber Assay for the Determination of Microtubule Disruption In vivo

- L12 ANSWER 21 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
- TI Preparation of quinone and catechol derivatives for the treatment of cancers and other vascular proliferative disorders

- L12 ANSWER 22 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
- TI Breast **cancer** resistance protein (BCRP) inhibitor

- L12 ANSWER 23 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
- TI Combretastatin family member OXI4503 induces tumor vascular collapse

through the induction of endothelial apoptosis

- L12 ANSWER 24 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
- TI Vascular therapy targeted at tubulin

- L12 ANSWER 25 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
- TI Vascular-targeting therapies for treatment of malignant disease

- L12 ANSWER 26 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
- TI Methods for quantifying ratio between two nucleic acids by NASBA for diagnosis and treatment of HIV-1, tumor or angiogenic disorders

- L12 ANSWER 27 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
- TI Methods for quantifying ratio between two nucleic acids by NASBA for diagnosis and treatment of HIV-1, tumor or angiogenic disorders

- L12 ANSWER 28 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
- TI Combretastatin A4 phosphate

- L12 ANSWER 29 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
- TI The **Cancer** Research UK experience of pre-clinical toxicology studies to support early clinical trials with novel **cancer** therapies

- L12 ANSWER 30 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
- TI Compositions and methods for treating **cancer** using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents

- L12 ANSWER 31 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
- TI Cardiovascular safety profile of combretastatin A4 phosphate in a single-dose phase I study in patients with advanced **cancer**

- L12 ANSWER 32 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
- TI Antitumor activity of TZT-1027 (Soblidotin) against vascular endothelial growth factor-secreting human lung **cancer** in vivo

- L12 ANSWER 33 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
- TI Preparation of resveratrol and sodium resverastatin phosphate derivatives for use in pharmaceutical compositions as antineoplastic and antimicrobial agents

- L12 ANSWER 34 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
- TI The vascular targeting agent combretastatin A-4-phosphate induces neutrophil recruitment to endothelial cells in vitro

- L12 ANSWER 35 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
- TI Combretastatin A-1 phosphate potentiates the antitumour activity of cisplatin in a murine adenocarcinoma model

- L12 ANSWER 36 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
- TI Heme oxygenase and the novel tumour-specific anti-vascular compound combretastatin A4-phosphate

- L12 ANSWER 37 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
- TI Synthesis, in vitro, and in vivo evaluation of phosphate ester derivatives of combretastatin A-4

- L12 ANSWER 38 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
- TI Enhancement of radiation therapy by vascular targeting agents

- L12 ANSWER 39 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
- TI Preparation of combretastatin A3 diphosphate prodrugs for the treatment of **cancer**

- L12 ANSWER 40 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Synergy between vascular targeting agents and antibody-directed therapy
- L12 ANSWER 41 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
 TI The development of combretastatin A4 phosphate as a vascular targeting agent
- L12 ANSWER 42 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Application of multiphoton steady state and lifetime imaging to mapping of tumor vascular architecture in vivo
- L12 ANSWER 43 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Schedule dependence of combretastatin A4 phosphate in transplanted and spontaneous tumor models
- L12 ANSWER 44 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
 TI A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced **cancer**
- L12 ANSWER 45 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Acute effects of vascular modifying agents in solid tumors assessed by noninvasive laser doppler flowmetry and near infrared spectroscopy
- L12 ANSWER 46 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Combretastatin A-1 phosphate a novel tubulin-binding agent with in vivo anti vascular effects in experimental tumours
- L12 ANSWER 47 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Antineoplastic Agents. 465. Structural Modification of Resveratrol: Sodium Resverastatin Phosphate
- L12 ANSWER 48 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Synthesis of disodium combretastatin A-4 3'-O-phosphate
- L12 ANSWER 49 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Oligopeptide-based prodrugs activated by plasmin and their use in **cancer** chemotherapy
- L12 ANSWER 50 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Preparation of combretastatin A-1 phosphate and combretastatin B-1 phosphate prodrugs with increased solubility
- L12 ANSWER 51 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Synthesis of hydroxyphenstatin and the prodrugs thereof as anticancer and antimicrobial agents
- L12 ANSWER 52 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Antineoplastic agents 463. Synthesis of combretastatin A-3 diphosphate prodrugs
- L12 ANSWER 53 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin A-4 3-O-phosphate
- L12 ANSWER 54 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Specific targeting of cytosine deaminase to solid tumors by engineered *Clostridium acetobutylicum*
- L12 ANSWER 55 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Antineoplastic agents 429. Syntheses of the combretastatin A-1 and combretastatin B-1 prodrugs

10/510,675


- L12 ANSWER 56 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
TI Antineoplastic Agents 440. Asymmetric Synthesis and Evaluation of the Combretastatin A-1 SAR Probes (1S,2S)- and (1R,2R)-1,2-Dihydroxy-1-(2',3'-dihydroxy-4'-methoxyphenyl)-2-(3'',4'',5''-trimethoxyphenyl)-ethane
- L12 ANSWER 57 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
TI Antineoplastic Agents. 443. Synthesis of the **Cancer** Cell Growth Inhibitor Hydroxyphenstatin and Its Sodium Diphosphate Prodrug
- L12 ANSWER 58 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
TI In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug
- L12 ANSWER 59 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation and formulation of combretastatin A4 prodrugs and their trans-isomers for use as antitumor agents
- L12 ANSWER 60 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
TI Antineoplastic agents 393. Synthesis of the trans-isomer of combretastatin A-4 prodrug
- L12 ANSWER 61 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
TI Antineoplastic Agents. 410. Asymmetric Hydroxylation of trans-Combretastatin A-4
- L12 ANSWER 62 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
TI Antineoplastic Agents. 379. Synthesis of Phenstatin Phosphate
- L12 ANSWER 63 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
TI Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature
- L12 ANSWER 64 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
TI Antineoplastic agents. 322. Synthesis of combretastatin A-4 prodrugs

=> d l12 28 bib fhitstr

- L12 ANSWER 28 OF 64 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:371961 CAPLUS
DN 140:368003
TI Combretastatin A4 phosphate
AU West, Catharine M. L.; Price, Pat
CS Academic Department of Radiation Oncology and Manchester Molecular Imaging Centre, University of Manchester, Christie NHS Trust Hospital, Manchester, M20 4BX, UK
SO Anti-Cancer Drugs (2004), 15(3), 179-187
CODEN: ANTDEV; ISSN: 0959-4973
PB Lippincott Williams & Wilkins
DT Journal; General Review
LA English
IT 222030-63-9, Combretastatin A4 phosphate
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antitumor action mechanism of combretastatin A4 phosphate)
RN 222030-63-9 CAPLUS
CN Phenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, dihydrogen phosphate (9CI) (CA INDEX NAME)

Double bond geometry as shown.

10/510,675



RE.CNT 83 THERE ARE 83 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file stnguide
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
33.48	369.31

FULL ESTIMATED COST

FILE 'STNGUIDE' ENTERED AT 09:43:32 ON 11 MAY 2006
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: May 5, 2006 (20060505/UP).

=> d his

(FILE 'HOME' ENTERED AT 09:27:33 ON 11 MAY 2006)

FILE 'REGISTRY' ENTERED AT 09:27:38 ON 11 MAY 2006

L1 STRUCTURE UPLOADED
L2 QUE L1
L3 0 S L2
L4 0 S L2 FUL

FILE 'STNGUIDE' ENTERED AT 09:29:22 ON 11 MAY 2006

FILE 'REGISTRY' ENTERED AT 09:33:21 ON 11 MAY 2006

L5 STRUCTURE UPLOADED
L6 QUE L5
L7 8 S L6
L8 159 S L6 FUL

FILE 'CAPLUS' ENTERED AT 09:34:34 ON 11 MAY 2006

L9 145 S L8
L10 145 DUP REM L9 (0 DUPLICATES REMOVED)
L11 145 S L10
L12 64 S L10 AND CANCER

FILE 'STNGUIDE' ENTERED AT 09:43:32 ON 11 MAY 2006

=> file reg
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.36	369.67

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 09:47:10 ON 11 MAY 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file

10/510,675

provided by InfoChem.

STRUCTURE FILE UPDATES: 10 MAY 2006 HIGHEST RN 883788-13-4
DICTIONARY FILE UPDATES: 10 MAY 2006 HIGHEST RN 883788-13-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

```
*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005. A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*
*****
```

Structure search iteration limits have been increased. See HELP SLIMITS
for details.


REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=>
Uploading C:\Documents and Settings\rkeys\My
Documents\STNEXP4\TEMPLATE\STANDARD\10510675b.str



chain nodes :

1 2 15 16 17 18 19 21 22 26 27

ring nodes :

3 4 5 6 7 8 9 10 11 12 13 14 28 29 30 31 32 33 34 35 36 37 38
39

chain bonds :

1-2 1-4 2-3 15-16 16-17 16-18 16-19 18-26 19-27 26-28 27-29

ring bonds :

3-10 3-14 4-5 4-9 5-6 6-7 7-8 8-9 10-11 11-12 12-13 13-14 28-30 28-34
29-35 29-39 30-31 31-32 32-33 33-34 35-36 36-37 37-38 38-39

exact/norm bonds :

10/510,675

15-16 16-17 16-18 16-19

exact bonds :

1-2 1-4 2-3 18-26 19-27 26-28 27-29

normalized bonds :

3-10 3-14 4-5 4-9 5-6 6-7 7-8 8-9 10-11 11-12 12-13 13-14 28-30 28-34
29-35 29-39 30-31 31-32 32-33 33-34 35-36 36-37 37-38 38-39

isolated ring systems :

containing 3 : 4 : 28 : 29 :

Match level :

1:CLASS 2:CLASS 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 26:CLASS 27:CLASS
28:Atom 29:Atom 30:Atom 31:Atom 32:Atom 33:Atom 34:Atom 35:Atom 36:Atom
37:Atom 38:Atom 39:Atom

L13 STRUCTURE UPLOADED

=> que L13

L14 QUE L13

=> d his

(FILE 'HOME' ENTERED AT 09:27:33 ON 11 MAY 2006)

FILE 'REGISTRY' ENTERED AT 09:27:38 ON 11 MAY 2006

L1 STRUCTURE UPLOADED

L2 QUE L1

L3 0 S L2

L4 0 S L2 FUL

FILE 'STNGUIDE' ENTERED AT 09:29:22 ON 11 MAY 2006

FILE 'REGISTRY' ENTERED AT 09:33:21 ON 11 MAY 2006

L5 STRUCTURE UPLOADED

L6 QUE L5

L7 8 S L6

L8 159 S L6 FUL

FILE 'CAPLUS' ENTERED AT 09:34:34 ON 11 MAY 2006

L9 145 S L8

L10 145 DUP REM L9 (0 DUPLICATES REMOVED)

L11 145 S L10

L12 64 S L10 AND CANCER

FILE 'STNGUIDE' ENTERED AT 09:43:32 ON 11 MAY 2006

FILE 'REGISTRY' ENTERED AT 09:47:10 ON 11 MAY 2006

L13 STRUCTURE UPLOADED

L14 QUE L13

=> s l14 sub=18

ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):full

FULL SUBSET SEARCH INITIATED 09:50:28 FILE 'REGISTRY'

FULL SUBSET SCREEN SEARCH COMPLETED - 16 TO ITERATE

100.0% PROCESSED 16 ITERATIONS

SEARCH TIME: 00.00.01

10 ANSWERS


10/510,675

L15 10 SEA SUB=L8 SSS FUL L13

=> d scan

L15 10 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Phosphoric acid, 5-[(1Z)-2-(3-fluoro-4,5-dimethoxyphenyl)ethenyl]-2-methoxyphenyl bis(phenylmethyl) ester (9CI)
MF C31 H30 F O7 P

Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):9

L15 10 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Phosphoric acid, 4-[(1Z)-2-(3,5-dimethoxyphenyl)ethenyl]phenyl bis(phenylmethyl) ester (9CI)
MF C30 H29 O6 P

Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L15 10 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Phosphoric acid, 2-methoxy-5-[(1E)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl bis(phenylmethyl) ester (9CI)
MF C32 H33 O8 P

Double bond geometry as shown.


10/510,675



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L15 10 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Phosphoric acid, 5-[(1Z)-2-(3-bromo-4,5-dimethoxyphenyl)ethenyl]-2-
methoxyphenyl bis(phenylmethyl) ester (9CI)
MF C31 H30 Br O7 P

Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L15 10 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Phosphoric acid, 2-bromo-3-methoxy-6-[(1Z)-2-(3,4,5-
trimethoxyphenyl)ethenyl]phenyl bis(phenylmethyl) ester (9CI)
MF C32 H32 Br O8 P

Double bond geometry as shown.


10/510,675



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L15 10 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Phosphoric acid, 3-methoxy-6-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-1,2-phenylene tetrakis(phenylmethyl) ester (9CI)
MF C46 H46 O12 P2

Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L15 10 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Phosphoric acid, 5-[(1Z)-2-(3-iodo-4,5-dimethoxyphenyl)ethenyl]-2-methoxyphenyl bis(phenylmethyl) ester (9CI)
MF C31 H30 I O7 P

Double bond geometry as shown.


10/510,675



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L15 10 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Phosphoric acid, 5-[(1Z)-1,2-difluoro-2-(3,4,5-trimethoxyphenyl)ethenyl]-2-methoxyphenyl bis(phenylmethyl) ester (9CI)
MF C32 H31 F2 O8 P

Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L15 10 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Phosphoric acid, (1Z)-1,2-ethenediylbis(6-methoxy-3,1-phenylene) tetrakis(phenylmethyl) ester (9CI)
MF C45 H44 O11 P2

Double bond geometry as shown.


10/510,675



****PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT****

```
L15 10 ANSWERS   REGISTRY   COPYRIGHT 2006 ACS on STN
IN  Phosphoric acid, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]pheny
MF  l bis(phenylmethyl) ester (9CI)
    C32 H33 O8 P
```

Double bond geometry as shown.



****PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT****

ALL ANSWERS HAVE BEEN SCANNED

```
=> file stnguide
COST IN U.S. DOLLARS
```

SINCE FILE	TOTAL
ENTRY	SESSION
42.48	412.15

FILE 'STNGUIDE' ENTERED AT 09:51:12 ON 11 MAY 2006
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: May 5, 2006 (20060505/UP).

10/510,675

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.18

412.33

FILE 'CAPLUS' ENTERED AT 09:52:48 ON 11 MAY 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 11 May 2006 VOL 144 ISS 20

FILE LAST UPDATED: 9 May 2006 (20060509/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l15

L16 15 L15

=> d his

(FILE 'HOME' ENTERED AT 09:27:33 ON 11 MAY 2006)

FILE 'REGISTRY' ENTERED AT 09:27:38 ON 11 MAY 2006

L1 STRUCTURE UPLOADED

L2 QUE L1

L3 0 S L2

L4 0 S L2 FUL

FILE 'STNGUIDE' ENTERED AT 09:29:22 ON 11 MAY 2006

FILE 'REGISTRY' ENTERED AT 09:33:21 ON 11 MAY 2006

L5 STRUCTURE UPLOADED

L6 QUE L5

L7 8 S L6

L8 159 S L6 FUL

FILE 'CAPLUS' ENTERED AT 09:34:34 ON 11 MAY 2006

L9 145 S L8

L10 145 DUP REM L9 (0 DUPLICATES REMOVED)

L11 145 S L10

L12 64 S L10 AND CANCER

FILE 'STNGUIDE' ENTERED AT 09:43:32 ON 11 MAY 2006

FILE 'REGISTRY' ENTERED AT 09:47:10 ON 11 MAY 2006

L13 STRUCTURE UPLOADED

L14 QUE L13

L15 10 S L14 SUB=L8 FULL

10/510,675

FILE 'STNGUIDE' ENTERED AT 09:51:12 ON 11 MAY 2006

FILE 'CAPLUS' ENTERED AT 09:52:48 ON 11 MAY 2006

L16 15 S L15

=> d 1-15 bib fhitr

L16 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:318869 CAPLUS

DN 144:350444

TI Preparation of halocombstastins for use in pharmaceutical compositions for the treatment of cancer

IN Pettit, George R.; Rosenberg, Heidi J.; Minardi, Matthew D.

PA Arizona Board of Regents, USA

SO PCT Int. Appl., 54 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006036743	A2	20060406	WO 2005-US33998	20050923
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	US 2005176688	A1	20050811	US 2004-948926	20040924
PRAI	US 2004-612888P	P	20040924		
	US 2004-948926	A	20040924		
	US 2003-505935P	P	20030924		

IT 861995-18-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of halocombretastatins for use in pharmaceutical compns. for treatment of cancer)

RN 861995-18-8 CAPLUS

CN Phosphoric acid, 5-[(1Z)-2-(3-fluoro-4,5-dimethoxyphenyl)ethenyl]-2-methoxyphenyl bis(phenylmethyl) ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



10/510,675

L16 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:1090333 CAPLUS

DN 144:22749

TI Antineoplastic Agents. 509. Synthesis of Fluorocombstatin Phosphate and Related 3-Halostilbenes

AU Pettit, George R.; Minardi, Mathew D.; Rosenberg, Heidi J.; Hamel, Ernest; Bibby, Michael C.; Martin, Sandie W.; Jung, M. Katherine; Pettit, Robin K.; Cuthbertson, Timothy J.; Chapuis, Jean-Charles

CS Cancer Research Institute and Department of Chemistry and Biochemistry, Arizona State University, Tempe, AZ, 85287-2404, USA

SO Journal of Natural Products (2005), 68(10), 1450-1458

CODEN: JNPRDF; ISSN: 0163-3864

PB American Chemical Society-American Society of Pharmacognosy

DT Journal

LA English

IT 861995-18-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of fluorocombstatin phosphate and related 3-halostilbenes, their human antitumor, tubulin polymerization inhibitory, and antimicrobial activities, and structure-activity relationship)

RN 861995-18-8 CAPLUS

CN Phosphoric acid, 5-[(1Z)-2-(3-fluoro-4,5-dimethoxyphenyl)ethenyl]-2-methoxyphenyl bis(phenylmethyl) ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:735316 CAPLUS

DN 143:193858

TI Preparation of combretastatin halogen derivatives for use in pharmaceutical compositions for the treatment of cancer

IN Pettit, George R.; Minardi, Mathew D.; Rosenberg, Heidi J.

PA Arizona Board of Regents, A Body Corporate of the State of Arizona, USA

SO U.S. Pat. Appl. Publ., 32 pp.

CODEN: USXXCO

DT Patent

LA English


FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005176688	A1	20050811	US 2004-948926	20040924
	WO 2006036743	A2	20060406	WO 2005-US33998	20050923
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,				

10/510,675

LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ,
NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG,
SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN,
YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM
PRAI US 2003-505935P P 20030924
US 2004-612888P P 20040924
US 2004-948926 A 20040924
OS MARPAT 143:193858
IT 861995-20-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(preparation of combretastatin halogen derivs. for use in pharmaceutical
compsns. for the treatment of cancer)
RN 861995-20-2 CAPLUS
CN Phosphoric acid, 5-[(1Z)-2-(3-iodo-4,5-dimethoxyphenyl)ethenyl]-2-
methoxyphenyl bis(phenylmethyl) ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L16 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:45407 CAPLUS

DN 142:134385

TI Preparation of combretastatin derivatives for use in pharmaceutical
compositions for the treatment of cancer and other hyperproliferative
diseases

IN Giannini, Giuseppe; Marzi, Mauro; Alloatti, Domenico; Tinti, Maria
Ornella; Riccioni, Teresa; Marcellini, Marcella

PA Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Italy

SO Brit. UK Pat. Appl., 34 pp.

CODEN: BAXXDU

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 2403949	A1	20050119	GB 2003-16910	20030718
	AU 2004257012	A1	20050127	AU 2004-257012	20040706
	CA 2531596	AA	20050127	CA 2004-2531596	20040706
	WO 2005007603	A2	20050127	WO 2004-IT375	20040706
	WO 2005007603	A3	20050707		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,

10/510,675

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

PRAI GB 2003-16910 A 20030718
WO 2004-IT375 W 20040706

OS MARPAT 142:134385

IT 824976-15-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation of combretastatin derivs. for use in pharmaceutical compns. for
treatment of cancer and other hyperproliferative diseases)

RN 824976-15-0 CAPLUS

CN Phosphoric acid, 5-[(1Z)-1,2-difluoro-2-(3,4,5-trimethoxyphenyl)ethenyl]-2-
methoxyphenyl bis(phenylmethyl) ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:836866 CAPLUS

DN 139:337828

TI Preparation of resveratrol and sodium resverastatin phosphate derivatives
for use in pharmaceutical compositions as antineoplastic and antimicrobial
agents

IN Pettit, George R.; Grealish, Matthew P.

PA Arizona Board of Regents, USA

SO PCT Int. Appl., 51 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003086414	A1	20031023	WO 2003-US11008	20030410
	W: CA, JP, US				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,				
	IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
	US 2005240062	A1	20051027	US 2004-510675	20041006
PRAI	US 2002-371782P	P	20020410		
	WO 2003-US11008	W	20030410		
OS	CASREACT 139:337828				
IT	441351-38-8P				


10/510,675

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of resveratrol and sodium resverastatin phosphate derivs. for use in pharmaceutical compns. as antineoplastic and antimicrobial agents)

RN 441351-38-8 CAPLUS

CN Phosphoric acid, 4-[(1Z)-2-(3,5-dimethoxyphenyl)ethenyl]phenyl bis(phenylmethyl) ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:334852 CAPLUS

DN 138:353746

TI Preparation of stilbenes as vascular targeting agents (VTAs) for treatment of solid tumors and retinal neovascularization.

IN Chaplin, David J.; Garner, Charles Manly, III; Kane, Robert Ronald; Pinney, Kevin G.; Prezioso, Joseph Anthony

PA Oxigene, Inc., USA; Evardsen, Klaus

SO PCT Int. Appl., 56 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003035008	A2	20030501	WO 2002-US34497	20021028
	WO 2003035008	A3	20031113		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2463902	AA	20030501	CA 2002-2463902	20021028
	US 2003149003	A1	20030807	US 2002-281528	20021028
	US 6919324	B2	20050719		
	EP 1438281	A2	20040721	EP 2002-797056	20021028
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
	JP 2005507912	T2	20050324	JP 2003-537577	20021028
	US 2006035868	A1	20060216	US 2005-183556	20050718
PRAI	US 2001-337348P	P	20011026		
	US 2002-281528	A3	20021028		
	WO 2002-US34497	W	20021028		
OS	MARPAT 138:353746				

10/510,675

IT 519060-32-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of stilbenes as vascular targeting agents (VTAs) for treatment of solid tumors and retinal neovascularization)

RN 519060-32-3 CAPLUS

CN Phosphoric acid, 2-bromo-3-methoxy-6-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl bis(phenylmethyl) ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L16 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:977780 CAPLUS

DN 138:55802

TI Preparation of combretastatin A3 diphosphate prodrugs for the treatment of cancer

IN Pettit, George R.; Minardi, Mathew D.

PA Arizona Board of Regents, USA

SO PCT Int. Appl., 33 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002102766	A2	20021227	WO 2002-US19085	20020617
	WO 2002102766	A3	20030403		
	W: CA, JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
	CA 2418102	AA	20021227	CA 2002-2418102	20020617
	EP 1395265	A2	20040310	EP 2002-746550	20020617
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
	JP 2004521939	T2	20040722	JP 2003-505309	20020617
	US 2004029838	A1	20040212	US 2003-398543	20030407
PRAI	US 2001-298606P	P	20010615		
	WO 2002-US19085	W	20020617		

IT 380892-70-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of combretastatin A3 diphosphate prodrugs for the treatment of cancer)

RN 380892-70-6 CAPLUS

CN Phosphoric acid, (1Z)-1,2-ethenediylbis(6-methoxy-3,1-phenylene) tetrakis(phenylmethyl) ester (9CI) (CA INDEX NAME)


10/510,675

Double bond geometry as shown.



L16 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:348358 CAPLUS
DN 137:87838
TI Antineoplastic Agents. 465. Structural Modification of Resveratrol: Sodium Resverastatin Phosphate
AU Pettit, George R.; Grealish, Matthew P.; Jung, M. Katherine; Hamel, Ernest; Pettit, Robin K.; Chapuis, J. Charles; Schmidt, Jean M.
CS Cancer Research Institute and Department of Chemistry and Biochemistry, Arizona State University, Tempe, AZ, 85287-2404, USA
SO Journal of Medicinal Chemistry (2002), 45(12), 2534-2542
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
OS CASREACT 137:87838
IT 441351-38-8P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation and antitumor structure activity relationships of resveratrol analogs)
RN 441351-38-8 CAPLUS
CN Phosphoric acid, 4-[(1Z)-2-(3,5-dimethoxyphenyl)ethenyl]phenyl bis(phenylmethyl) ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:72094 CAPLUS
DN 136:134622

10/510,675

TI Methods of synthesizing prodrugs of combretastatin A-4
IN Seyedi, Faye; Gale, Jonathan; Haider, Reem; Hoare, John
PA Oxigene, Inc., USA
SO PCT Int. Appl., 41 pp.

CODEN: PIXXD2

DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002006279	A1	20020124	WO 2001-US22403	20010717
	WO 2002006279	C1	20020418		
	WO 2002006279	C2	20030403		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2002119951	A1	20020829	US 2001-908321	20010717
	US 6743937	B2	20040601		
PRAI	US 2000-218766P	P	20000717		

OS CASREACT 136:134622


IT 208465-88-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(methods of synthesizing prodrugs of combretastatin A-4)

RN 208465-88-7 CAPLUS

CN Phosphoric acid, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl bis(phenylmethyl) ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L16 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2001:798232 CAPLUS

DN 135:344595

TI Preparation of combretastatin A-1 phosphate and combretastatin B-1 phosphate prodrugs with increased solubility

IN Pettit, George R.; Lippert, John W., III

PA Arizona Board of Regents, A Body Corporate of the State of Arizona, Acting for and On Behalf of Arizona State University, USA

SO PCT Int. Appl., 41 pp.

CODEN: PIXXD2


DT Patent
LA English

10/510,675

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001081355	A1	20011101	WO 2001-US13858	20010427
	W: CA, JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
	CA 2407675	AA	20011101	CA 2001-2407675	20010427
	EP 1278758	A1	20030129	EP 2001-928978	20010427
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
	US 2003220298	A1	20031127	US 2002-258672	20021025
PRAI	US 2000-200395P	P	20000427		
	WO 2001-US13858	W	20010427		
OS	CASREACT 135:344595				
IT	313692-35-2P, 2',3'-O-di[bis-benzylphosphoryl]-combretastatin A-1				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)				
	(preparation, reduction of double bond and conversion to sodium salt)				
RN	313692-35-2 CAPLUS				
CN	Phosphoric acid, 3-methoxy-6-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-1,2-phenylene tetrakis(phenylmethyl) ester (9CI) (CA INDEX NAME)				

Double bond geometry as shown.




RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:612313 CAPLUS
DN 136:31380
TI Antineoplastic agents 463. Synthesis of combretastatin A-3 diphosphate prodrugs
AU Pettit, George R.; Minardi, Mathew D.; Boyd, Michael R.; Pettit, Robin K.
CS Cancer Research Institute and Department of Chemistry and Biochemistry, Arizona State University, Tempe, AZ, 85287-2404, USA
SO Anti-Cancer Drug Design (2001), Volume Date 2000, 15(6), 397-403
CODEN: ACDDEA; ISSN: 0266-9536
PB Oxford University Press
DT Journal
LA English
IT 380892-70-6P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(synthesis of combretastatin A-3 and its diphosphate prodrugs as antineoplastic agents)
RN 380892-70-6 CAPLUS

10/510,675

CN Phosphoric acid, (1Z)-1,2-ethenediylbis(6-methoxy-3,1-phenylene) tetrakis(phenylmethyl) ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2000:757705 CAPLUS

DN 134:51116

TI Antineoplastic agents 429. Syntheses of the combretastatin A-1 and combretastatin B-1 prodrugs

AU Pettit, George R.; Lippert, John W., III

CS Cancer Research Institute and Department of Chemistry and Biochemistry, Arizona State University, Tempe, AZ, 85287-2404, USA

SO Anti-Cancer Drug Design (2000), 15(3), 203-216

CODEN: ACDDEA; ISSN: 0266-9536

PB Oxford University Press

DT Journal

LA English

IT 313692-35-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of antineoplastic agents, combretastatin A-1 and combretastatin B-1 prodrugs)

RN 313692-35-2 CAPLUS

CN Phosphoric acid, 3-methoxy-6-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-1,2-phenylene tetrakis(phenylmethyl) ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



10/510,675

RE.CNT 94 THERE ARE 94 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1999:451301 CAPLUS

DN 131:73507

TI Preparation and formulation of combretastatin A4 prodrugs and their
trans-isomers for use as antitumor agents

IN Pettit, George R.; Rhodes, Monte R.

PA Arizona State University, USA

SO PCT Int. Appl., 55 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 9935150	A1	19990715	WO 1999-US419	19990108
	W: CA, JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2314238	AA	19990715	CA 1999-2314238	19990108
	EP 1045853	A1	20001025	EP 1999-902121	19990108
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	JP 2002500227	T2	20020108	JP 2000-527548	19990108
	US 7018987	B1	20060328	US 2000-582950	20000707
PRAI	US 1998-71070P	P	19980109		
	US 1998-111531P	P	19981209		
	WO 1999-US419	W	19990108		
IT	229178-27-2P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)				
	(preparation and formulation of combretastatin A4 prodrugs and their trans-isomers for use as antitumor agents)				
RN	229178-27-2 CAPLUS				
CN	Phosphoric acid, 2-methoxy-5-[(1E)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl bis(phenylmethyl) ester (9CI) (CA INDEX NAME)				

Double bond geometry as shown.




RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/510,675

L16 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:284035 CAPLUS
DN 131:82669
TI Antineoplastic agents 393. Synthesis of the trans-isomer of combretastatin A-4 prodrug
AU Pettit, George R.; Rhodes, Monte R.; Herald, Delbert L.; Chaplin, Dai J.; Stratford, Michael R. L.; Hamel, Ernest; Pettit, Robin K.; Chapuis, Jean-Charles; Oliva, Deanna
CS Cancer Research Institute and Department of Chemistry, Arizona State University, Tempe, AZ, 85287-2494, USA
SO Anti-Cancer Drug Design (1998), 13(8), 981-993
CODEN: ACDDEA; ISSN: 0266-9536
PB Oxford University Press
DT Journal
LA English
IT 229178-27-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis of the antitumor trans-isomer of combretastatin A-4 prodrug)
RN 229178-27-2 CAPLUS
CN Phosphoric acid, 2-methoxy-5-[(1E)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl bis(phenylmethyl) ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:301433 CAPLUS
DN 129:36213
TI Antineoplastic agents. 389. New syntheses of the combretastatin A-4 prodrug
AU Pettit, George R.; Rhodes, Monte R.
CS Cancer Research Institute and Department of Chemistry, Arizona State University, Tempe, AZ, 85287-2404, USA
SO Anti-Cancer Drug Design (1998), 13(3), 183-191
CODEN: ACDDEA; ISSN: 0266-9536
PB Oxford University Press
DT Journal
LA English
IT 208465-88-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


10/510,675

(preparation of combretastatin A-4 prodrug)

RN 208465-88-7 CAPLUS

CN Phosphoric acid, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl bis(phenylmethyl) ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file stnguide

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

53.11

465.44

FILE 'STNGUIDE' ENTERED AT 09:53:29 ON 11 MAY 2006

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE

AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: May 5, 2006 (20060505/UP).

=> log hold

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION



FULL ESTIMATED COST

1.02

466.46

SESSION WILL BE HELD FOR 60 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 10:03:52 ON 11 MAY 2006



chain nodes :

1 2 15 16 17 18 19 21 22

ring nodes :

3 4 5 6 7 8 9 10 11 12 13 14 25 26 27 28 29 30 31 32 33 34 35 36

chain bonds :

1-2 1-4 2-3 15-16 16-17 16-18 16-19 18-25 19-26

ring bonds :

3-10 3-14 4-5 4-9 5-6 6-7 7-8 8-9 10-11 11-12 12-13 13-14 25-27 25-31 26-32
26-36 27-28 28-29 29-30 30-31 32-33 33-34 34-35 35-36

exact/norm bonds :

15-16 16-17 16-18 16-19 18-25 19-26

exact bonds :

1-2 1-4 2-3

normalized bonds :



3-10 3-14 4-5 4-9 5-6 6-7 7-8 8-9 10-11 11-12 12-13 13-14 25-27 25-31 26-32
26-36 27-28 28-29 29-30 30-31 32-33 33-34 34-35 35-36

isolated ring systems :

containing 3 : 4 : 25 : 26 :

Match level :

1:CLASS 2:CLASS 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS
21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom
30:Atom 31:Atom 32:Atom 33:Atom 34:Atom 35:Atom 36:Atom



chain nodes :

1 2 15 16 17 18 19 21 22

ring nodes :

3 4 5 6 7 8 9 10 11 12 13 14

chain bonds :

1-2 1-4 2-3 15-16 16-17 16-18 16-19

ring bonds :

3-10 3-14 4-5 4-9 5-6 6-7 7-8 8-9 10-11 11-12 12-13 13-14

exact/norm bonds :

15-16 16-17 16-18 16-19

exact bonds :

1-2 1-4 2-3

normalized bonds :



3-10 3-14 4-5 4-9 5-6 6-7 7-8 8-9 10-11 11-12 12-13 13-14

isolated ring systems :

containing 3 : 4 :

Match level :

1:CLASS 2:CLASS 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS
21:CLASS 22:CLASS 23:CLASS 24:CLASS



```

chain nodes :
  1  2 15 16 17 18 19 21 22 26 27
ring nodes :
  3  4  5  6  7  8  9 10 11 12 13 14 28 29 30 31 32 33 34 35 36 37 38 39
chain bonds :
  1-2 1-4 2-3 15-16 16-17 16-18 16-19 18-26 19-27 26-28 27-29
ring bonds :
  3-10 3-14 4-5 4-9 5-6 6-7 7-8 8-9 10-11 11-12 12-13 13-14 28-30 28-34 29-35
  29-39 30-31 31-32 32-33 33-34 35-36 36-37 37-38 38-39
exact/norm bonds :
  15-16 16-17 16-18 16-19
exact bonds :
  1-2 1-4 2-3 18-26 19-27 26-28 27-29
normalized bonds :
  3-10 3-14 4-5 4-9 5-6 6-7 7-8 8-9 10-11 11-12 12-13 13-14 28-30 28-34 29-35
  29-39 30-31 31-32 32-33 33-34 35-36 36-37 37-38 38-39
isolated ring systems :
  containing 3 : 4 : 28 : 29 :
  
```

```

Match level :
  1:CLASS 2:CLASS 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
  12:Atom 13:Atom 14:Atom 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS
  21:CLASS 22:CLASS 23:CLASS 24:CLASS 26:CLASS 27:CLASS 28:Atom 29:Atom 30:Atom
  31:Atom 32:Atom 33:Atom 34:Atom 35:Atom 36:Atom 37:Atom 38:Atom 39:Atom
  
```